SCHEMBL5872816

SCHEMBL5872816

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(C(=O)NCCCn2ccnc2)c(F)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
POLB P06746 2/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HTT P42858 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NAMPT P43490 1/20 0.44
CYP19A1 P11511 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872818 0.97 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL5872857 0.81 BCL3 (0.48) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL5872919 0.79 RAB9A (0.49) KMT2AKDM4EALDH1A1LMNAHSD17B10
SCHEMBL5872768 0.79 SORT1 (0.47) MEN1KMT2AHSD17B10TDP1HTT
SCHEMBL5872804 0.77 BCL3 (0.47) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL5872815 0.77 SMN1; SMN2 (0.44) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL5872850 0.76 MAP2K1 (0.56) MEN1KMT2ATDP1SMN1; SMN2
SCHEMBL5872844 0.76 KMT2A (0.47) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL5872772 0.76 MEN1 (0.42) MEN1KMT2ATDP1
SCHEMBL5872900 0.76 MAP2K1 (0.48) MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 MEN1 2841/4885KMT2A 636/4885KDM4E 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.